Malaysian scientists publish the very latest results on colorectal cancer screening using the M2-PK rapid test in the renowned journal PLOS ONE

Kuala Lumpur. Scientists from the Department of Medicine at the University of Malaysia have recently presented the very latest data from a study on colorectal cancer screening using the M2-PK stool test in the renowned publi-cation PLOS ONE. These latest results for the M2-PK test from the cancer specialist Professor Khean-Lee Goh - one of the most renown experts in Asia on this subject - and his colleagues confirm once again the exceptionally high capability and accuracy of the M2-PK test for colorectal cancer screening.

Professor Goh investigated the enyzme biomarker M2-PK in a patient group with 100 colorectal cancer cases and a population-based control group of 200 healthy people. The M2-PK test detected 93% of colorectal cancers. Furthermore, it recognized 97.5% of the control group as truly healthy. The positive predictive value for colorectal cancer was 94.9% and the predictive value to exclude colorectal cancer (negative predictive value) was 96.5%. The overall accuracy of the M2-PK test was 96%.

The investigators also made two additional important findings. Firstly, the M2-PK test has a very high detection rate (sensitivity) for right-sided (85.7%) as well as for left-sided colorectal cancers (94.2%). This result is especially important because right-sided colorectal cancers are more often missed than left-sided with conventional screening methods.

Secondly, M2-PK had almost the same very high rate of detection (sensitivity) across all four tumour stages (stage 1 = 94.1%; stage 2 = 88.9%; stage 3 = 96.4%; stage 4 = 90.3%).

The M2-PK rapid stool test is available for the doctors‘ practice as ScheBo(R) • M2-PK Quick(TM) (ScheBo(R) • Bio-tech AG).

Source: K.-L. Goh, et al.: http://dx.doi.org/10.1371/journal.pone.0131616

CONTACT:

ScheBo(R) • Biotech AG

phone +49-(0)641-4996-0

fax +49-(0)641-4996-78

www.schebo.com